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Abstract 
 
The relationship between Alzheimer’s disease (AD) and depression has been well 
established in terms of epidemiological and clinical observations. Depression has been 
considered to be both a symptom and risk factor of AD. Several genetic and 
neurobiological mechanisms have been described to underlie these two disorders. Despite 
the accumulating knowledge on this topic, the precise neuropathological mechanisms 
remain to be elucidated. In this study, we propose that synaptic degeneration plays an 
important role in the disease progression of depression and AD. Using primary culture of 
hippocampal neurons treated with oligomeric Aβ and corticosterone as model agents for 
AD and depression, respectively, we found significant changes in the pre-synaptic vesicle 
proteins synaptophysin and synaptotagmin. We further investigated whether the observed 
protein changes affected synaptic functions. By using FM
®
4-64 fluorescent probe, we 
showed that synaptic functions were compromised in treated neurons. Our findings led us 
to investigate the involvement of protein degradation mechanisms in mediating the 
observed synaptic protein abnormalities, namely, the ubiquitin-proteasome system and 
autophagy. We found up-regulation of ubiquitin-mediated protein degradation, and the 
preferential signaling for the autophagic-lysosomal degradation pathway. Lastly, we 
investigated the neuroprotective role of different classes of antidepressants. Our findings 
demonstrated that the antidepressants Imipramine and Escitalopram were able to rescue 
the observed synaptic protein damage. In conclusion, our study shows that synaptic 
degeneration is an important common denominator underlying depression and AD, and 
alleviation of this pathology by antidepressants may be therapeutically beneficial.  
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1. Introduction 
 
Alzheimer’s disease (AD) is characterized by progressive degeneration of the 
brain and its functions. As a result, AD patients present with memory deficits, cognitive 
decline, and diverse behavioral changes [1]. Neuropsychiatric symptoms are observed 
throughout the course of AD. They occur along the progression of disease and may even 
occur prior to significant decline in cognitive [2]. Such symptoms include depression, 
apathy, agitation, and hallucinations. Combined with cognitive deterioration, these 
symptoms compound patient disability and caregiver burden [3].  
 
AD is represented by two pathological hallmarks, namely β-amyloid (Aβ) plaques 
and neurofibrillary tangles (NFT). Studies have shown that abnormally folded Aß and tau 
proteins trigger cascades of neurodegenerative processes, including dysregulation of 
cholinergic neurons, synaptic degeneration, neuroinflammation, autophagy, and apoptosis 
[1]. 
 
Depression is one of the neuropsychiatric symptoms frequently observed in AD. It 
is characterized by prolonged period of low mood, anhedonia, and changes in sleep and 
appetite. Prevalence of depression in AD patients ranges from 20 to 50%. Studies have 
also shown that depressive symptoms may precede cognitive decline [3, 4].  
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A number of risk factors for depression in AD patients have been identified: 
family history of mood disorder in first-degree relatives, past history of depression, 
female gender, and early onset AD [5, 6]. A history of depression itself has also been 
associated with increased risks of developing AD, especially among elderly women [5, 7]. 
Several genetic risk factors have been identified to influence the development of 
depression and AD, including brain-derived neurotrophic factor genetic variation and 
being heterozygote for promoter region of interleukin-1β [8, 9]. 
 
Several neurobiological mechanisms have been found to cause cellular damage 
leading to depression. They include hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction, monoamine deficiency, neuroinflammation, and neuroplastic changes [10]. 
HPA axis dysfunction appears to be responsible for a great extent of the abnormalities 
observed in depression. HPA axis dysfunction results in prolonged release of the stress 
hormone, cortisol, which has been found to be elevated in depressed patients [11]. 
Cortisol binds to membrane mineralocorticoid and glucocorticoid receptors which allows 
for rapid modulation of synaptic transmission in the brain [12]. The hippocampus is of 
particular importance because it is rich in corticosteroid receptors, and structural changes 
in this brain region has been observed in depressed patients [13]. 
 
In the case of AD, high levels of corticotropin-releasing hormone and cortisol, 
secondary to HPA axis deregulation, have been found to increase the risk and rate of 
disease progression [14]. Adrenocortical hyperactivity was found to be associated with 
increased Aβ plaque deposition and NFT formation in an animal model of AD [15]. 
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Furthermore, cholinergic dysfunction found in AD has been shown to suppress 
glucocorticoid receptor feedback regulation of the HPA axis [16]. Prolonged release of 
cortisol and HPA axis activation is detrimental to the glucocorticoid-rich hippocampus, 
which is one of the earliest areas to be affected in AD [17]. 
 
It appears that the pathophysiological mechanisms underlying depression are 
common in AD. For instance, dysregulation of neurotransmitter systems, 
neuroinflammation and changes in neuroplasticity have been observed in both disorders. 
Studies are beginning to demonstrate the role of such mechanisms linking depression and 
AD [18, 19]. We are particularly interested in neuroplastic changes at the synapse, as 
they are sites of neuronal communication that are essential for proper brain functions. 
Synaptic plasticity has also been shown to be essential for learning and memory [20]. 
 
 In AD, altered expressions of synaptic proteins were found to occur early in the 
disease processes [21] and synaptic degeneration was found to correlate best with 
cognitive decline [22, 23]. Aβ has been shown to impair synaptic functions and spine 
structure in animal models of AD [24]. Furthermore, reduction of pre-synaptic vesicle 
proteins such as synaptophysin has been consistently observed in transgenic AD mouse 
models [25-27]. In conjunction with loss of pre-synaptic proteins, loss in post-synaptic 
proteins such as post-synaptic density 95 (PSD95) and glutamate receptor subunit GluR1 
has also been demonstrated [28-30].  
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Synaptic disturbances have also been shown to be involved in several psychiatric 
disorders, including autism, schizophrenia and bipolar disorder [20, 31]. Evidence 
suggests altered synaptic structure and functions in depression as well. Loss of 
hippocampal volume due to reduced neurogenesis has been observed in depressed 
patients [32, 33]. Reduction in neurogenesis and levels of synaptophysin have been 
shown in a chronic unpredictable mild stress rat model of depression [34]. In another 
stressed rat model of depression, dendritic spine loss was observed [35]. Furthermore, 
over-expression of pre-synaptic protein, piccolo, was found to induce depressive-like 
behavior in mice [36]. These studies provide evidence that stress is involved in altered 
synaptic functions, which in turn leads to the development of depression. 
 
Several mechanisms are involved in the disruption of synaptic functions. They 
include alterations in BDNF and disrupted synaptic signaling pathways responsible for 
synaptic maturation, impaired synaptic mitochondrial dynamics, and oxidative stress 
induced variations in synaptic genes [37-39]. 
 
Taking into consideration the importance of synapses in maintaining proper brain 
function and the role of its dysfunction in psychiatric disorders, we hypothesize that 
synaptic degeneration could be a common link between depression and AD. Since 
various classes of antidepressants have been the mainstay of depression pharmacotherapy, 
we also hypothesize that they will be able to ameliorate signs of synaptic damage. This 
will provide a platform for future drug development to prevent synaptic degeneration in 
the treatment of depression in AD. 
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2. Materials and methods 
 
2.1 Cell culture models 
 
 Primary culture of hippocampal neurons was used in this study (Supplementary 
Materials and methods). The hippocampal area was chosen because it is one of the 
affected areas in both depression and AD. The hippocampus plays important roles in 
memory consolidation and is one of the earliest affected areas in AD brains [40]. 
Moreover, the hippocampus contains a large number of glucocorticoid receptors, making 
it prone to chronic stress, which is highly implicated in depression [41]. Lastly, reduction 
in hippocampal volume has been observed in both disorders [33, 42]. 
  
Oligomeric Aβ1-42 was used as a model agent to represent AD pathologies. 
Corticosterone (CORT), a rodent derivative of cortisol, was used as a model agent for 
depression. Both chemicals were used at a sub-lethal dosage to simulate early disease 
events. 
 
Oligomeric Aβ was reconstituted in anhydrous dimethylsulfoxide (DMSO) 
(Supplementary Materials and methods) and CORT (Sigma-Aldrich, St. Louis, MO, USA) 
was reconstituted in 100% ethanol. Both agents were diluted in culture medium to the 
desired concentration for treatment. The same concentration of anhydrous DMSO or 
100% ethanol was diluted in culture medium as control.  
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 To investigate the neuroprotective effects of antidepressants, neurons were pre-
treated with Imipramine (Sigma-Aldrich) and Escitalopram (Lundbeck, Copenhagen, 
Denmark) for 1 hr, and incubated in either oligomeric Aβ or CORT for 24 hr. Imipramine 
and Escitalopram were dissolved in milliQ water and further diluted in culture medium to 
the desired concentration for treatment.  
 
2.2 Immunocytochemistry 
 
 For immunocytochemical staining, primary hippocampal neurons cultured on 
coverslips (Thermo Scientific) were fixed with 4% paraformaldehyde (PFA) for 20 min, 
permeabilized with 0.1% Triton X-100 in TBS for 7 min, and blocked with 10% bovine 
serum albumin for 1 hr. Incubation of primary antibody was done for 1 hr at room 
temperature at 1:400 dilution for the following antibodies: synaptophysin (Chemicon, 
Temecula, CA, USA) and synaptotagmin (Calbiochem, La Jolla, CA, USA). Ubiquitin-48 
(Millipore, Billerica, MA, USA), ubiquitin-63 (Millipore), and LC3-II (MBL 
International, Woburn, MA, USA) were incubated overnight at 4°C at 1:400. Neurons 
were then incubated with secondary antibody (Anti-rabbit or mouse, Alexa-fluor 488 or 
568, 1:400, Molecular Probes, Eugene, OR, USA) and mounted on microscope slides 
(Thermo Fisher Scientific, Waltham, MA, USA) using ProLong
®
 Gold antifade mounting 
medium (Invitrogen) and imaged using the LSM510-meta laser scanning confocal 
microscope (Carl Zeiss, Oberkochen, Germany). Images were analyzed using 
MacBiophotonics Image J (http://rsb.info.nih.gov/ij/). 
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2.3 Transduction 
 
Neurons cultured on MatTek dishes were transduced with 10 particles per cell of 
CellLight
® 
Synaptophysin-GFP (Invitrogen) overnight, prior to treatment. After treatment, 
neurons were imaged using the LSM510 confocal microscope. Images were then 
analyzed using MacBiophotonics Image J. 
 
2.4 FM
®
4-64 fluorescent probe 
 
 Five micromolar of FM
®
4-64 (Invitrogen) fluorescent probe was added to 
hippocampal neurons cultured on coverslips. The neurons were stimulated with 100 mM 
potassium chloride for 3 min to induce endocytosis. They were then washed with HBSS 
and incubated in the dye for 30 min at 37°C and 5% CO2 for complete endocytosis. One 
group was fixed with 4% PFA for 20 min. The remaining neurons were then washed and 
stimulated again with 100 mM potassium chloride for 10 min to induce exocytosis. The 
second group of neurons was then fixed with 4% PFA for 20 min. The coverslips were 
mounted on microscope slides using ProLong
®
 Gold antifade mounting medium 
(Invitrogen), analyzed using the LSM510 confocal microscope and quantified using 
MacBiophotonics Image J. 
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2.5 Western blot analysis 
 
 Total cell lysate were extracted by ice-cold lysis buffer containing 10 mM Tris 
(pH 7.4), 100 mM NaCl, 1 mM EDTA, 1mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 1% 
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, phenylmethylsulfonyl 
fluoride (1 mM), protease inhibitor cocktail and phosphatase inhibitor cocktail. The 
lysate was then sonicated, centrifuged at 14,000 rpm for 30 min at 4°C, and the 
supernatant was collected for analysis. Protein concentration was measured as directed in 
the protein assay kit (Bio-Rad, Hercules, CA, USA). Protein extracts were separated by 
SDS-PAGE gel and transferred onto PVDF membrane (Bio-Rad). The membrane was 
blocked with 5% non-fat milk (Bio-Rad) overnight. Primary antibodies for synaptophysin 
(Abcam) and synaptotagmin (Abcam) were incubated for 4 hr at 1:2000 dilutions and ß-
actin (Sigma) were incubated for 1 hr at 1:5000. Western blots were subsequently 
incubated with horseradish peroxidase-conjugated secondary antibody for 45 min. Bands 
were visualized on Biomax X-ray film using ECL spray (Upstate). Bands were quantified 
using MacBiophotonics Image J. 
 
2.6 Proteasome activity assay 
 
 Total cell lysate were harvested with ice cold lysis buffer containing 20 mM Tris, 
pH 7.2, 1 mM EDTA, 1 mM NaN3, 1 mM DTT, and protease inhibitor cocktail on ice 
and centrifuged for 10 min at 20,000 g. Supernatants were quantified in triplicate in black 
OptiPlate™ 96 well plates (Perkin Elmer, Waltham, USA). Background proteolytic 
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activity was controlled for by incubation of duplicate samples with 20 µM MG132 
(Boston Biochem, Cambridge, MA, USA) prior to incubation with fluorogenic substrates. 
N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (Suc-LLVY-AMC) (Enzo Life 
Sciences, Farmingdale, USA) for chymotrypsin-like activity, butoxycarbonyl-Leu-Arg-
Arg-amido-4-methylcoumarin (Boc-LRR-AMC) (Enzo Life Sciences) for trypsin-like 
activity, and benzyloxycarbonyl-Leu-Leu-Glu-amido-4-methylcoumarin (Z-LLE-AMC) 
(Enzo Life Sciences) for caspase-like activity, were incubated with samples at 20 µM for 
45 min at 37°C. Fluorescence was read on a microplate reader (Perkin Elmer) at 390 nm 
excitation and 460 nm emission. Fluorescence activity of all three proteasome proteolytic 
sites was taken as the level of fluorescence measured after subtraction from background.  
 
2.7 Statistical analysis 
 
Statistical comparison between two groups was determined by unpaired t-test. 
Data for multiple variable comparisons were analyzed by one-way analysis of variance 
(ANOVA). For the comparison of significance, Tukey’s test was used as a post hoc test. 
The statistical program used was GraphPad Prism (GraphPad Software, La Jolla, CA, 
USA). Results were expressed as mean ± standard error (S.E.) from at least three 
independent experiments. 
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3. Results 
 
3.1 Oligomeric Aβ and CORT caused pre-synaptic damage 
 
 To investigate the effects of low-dose oligomeric Aβ and CORT on the pre-
synaptic site, hippocampal neurons were treated with oligomeric Aβ or CORT at 0.5 μM 
for 24 hr and immunocytochemical analyses were performed for synaptophysin and 
synaptotagmin. Primary hippocampal neurons were also transduced with CellLight
® 
Synaptophysin-GFP for live-cell imaging. The number of immunoreactive positive 
puncta of synaptophysin and synaptotagmin was reduced after 24 hr of Aβ treatment (Fig. 
1 A-E). Aggregation of synaptophysin and synaptotagmin was observed after treatment 
with 0.5 μM Aβ for 12 hr (Fig. 1 A, F & G). Protein expression of synaptophysin and 
synaptotagmin was reduced with 0.5 and 5 μM Aβ treatment by western blot analysis 
(Fig. 1 H-J). CORT induced aggregation of the synaptic proteins (Fig. 2 A-D), without 
affecting the total protein expression level (Fig. 2 E & F).  
 
3.2 Oligomeric Aβ and CORT compromised synaptic functions 
 
To investigate whether the observed pathological changes affected synaptic 
functions, we employed the FM
®
4-64 fluorescent probe, which is commonly used to 
examine endocytosis and exocytosis. Endocytosis is monitored by dye uptake and the 
subsequent increase in fluorescent intensity. Exocytosis is examined by dye release and 
the subsequent decrease in fluorescent intensity. Images shown in the figure represent 
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dye uptake and release specifically at the neuritis (Fig. 3). Oligomeric Aβ and CORT 
treatment at 0.5 μM showed similar fluorescent intensities compared to control during 
dye uptake, indicating that endocytosis was unaffected (Fig. 3 A & B). However, during 
exocytosis when the dye was supposed to be released (and the subsequent decrease in 
fluorescent intensity), the fluorescent intensity of the treated neurons remained at a high 
level (Fig. 3 A & C), suggesting an impairment in exocytosis following oligomeric Aβ 
and CORT treatment.  
 
3.3 Involvement of protein degradation mechanisms at the synapse 
 
Since our results showed loss and aggregations of synaptic protein, we further 
investigated the mechanisms underlying the clearance of aggregated synaptic proteins. 
We found that oligomeric Aβ and CORT at 0.5 μM influenced ubiquitin-mediated protein 
degradation mechanisms, indicated by the increase in the immunoreactivity of ubiquitin-
48 and ubiquitin-63 (Fig. 4 A & B, D & E). Ubiquitin-63 was found to significantly co-
localize with synaptophysin (Fig. 4 D & F). On the other hand, ubiquitin-48 was found in 
close proximity to synaptophysin, but did not significantly co-localize (Fig. 4 A & C). 
Lactacystin, a proteasome inhibitor, served as a positive control for ubiquitin 
accumulation. 
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3.4 Corticosterone and oligomeric Aβ did not affect proteasome activity 
 
 Since oligomeric Aβ and CORT were found to induce an increased co-
localization between synaptophysin with ubiquitin-63 but not with ubiquitin-48, the 
ubiquitin-proteasome pathway may not be the major pathway or mechanism being 
affected in oligomeric Aβ- and CORT-treated cells. Therefore, we went on to examine 
whether oligomeric Aβ and CORT treatment affect proteasome activity within our model. 
Our results found no significant changes in the chymotrypsin-like, trypsin-like and 
caspase-like activity of the proteasome in both treatment groups (Fig. 5).  
 
3.5 Antidepressants were able to alleviate pathological changes of pre-synaptic 
proteins 
 
Antidepressants that target the monoaminergic system have long been used in the 
treatment of major depressive disorder. Therefore, we investigated if they could alleviate 
the pre-synaptic damage exerted by oligomeric Aβ and CORT treatment. Results 
demonstrated that pre-treatment with 10 μM Imipramine or Escitalopram for 1 hr was 
able to rescue the observed synaptic pathologies (Fig. 6). For oligomeric Aβ treated cells, 
immunofluorescent analysis of synaptophysin and synaptotagmin showed a significant 
increase in the number of positive puncta after pre-treatment with antidepressants (Fig. 6 
A-C). Pre-treatment with Imipramine or Escitalopram was able to reduce the number of 
synaptic protein aggregations in CORT-treated neurons (Fig.6 D-F).  
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4. Discussions 
 
Depression and AD share common pathophysiological characteristics including 
synaptic degeneration [43]. Synaptic degeneration is reflected by pathological changes 
within the molecular components of pre- and post-synaptic compartments [20]. Our 
results showed damages in the pre-synaptic compartment, which was found to affect the 
recycling of synaptic vesicles and ultimately the function of the synapse. Next, we found 
that ubiquitin-mediated protein degradation mechanisms appeared to be responsible for 
the clearance of aggregated synaptic proteins, which may mediate the degenerative 
processes. Furthermore, we found that antidepressants were able to alleviate the observed 
pre-synaptic damage. 
 
4.1 Synaptic damage 
 
Our results showed the pre-synaptic compartment was damaged after treatment 
with oligomeric Aβ and CORT. Pre-synaptic protein aggregation was observed after 12 
hr of treatment with Aβ, and protein loss was observed at 24 hr (Fig. 1). Although these 
changes were present, the dosage used did not significantly affect cell viability or induce 
apoptosis (Supplementary Fig. 1& 2). With CORT, pre-synaptic protein aggregation but 
not protein loss was observed 24 hr after treatment (Fig. 2). These observations suggest 
that pre-synaptic proteins undergo aggregation, followed by loss of proteins. Since there 
was no significant change in PSD95 following treatment with Aβ and CORT 
(Supplementary Fig. 3&4), it appeared that pre-synaptic damage occurred before post-
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synaptic damage. There is a possibility that PSD95 could be affected after 24 hr; however, 
longer treatment durations were not investigated. Despite the temporal differences in the 
occurrence of the synaptic pathologies, the pre-synaptic damage induced by CORT 
resembled that induced by oligomeric Aβ. 
 
Our next question was whether the observed morphological changes would affect 
synaptic functions. Synaptic vesicles undergo trafficking, docking, fusion to the synaptic 
membrane, and ultimately the release of neurotransmitters. After neurotransmitter release, 
empty synaptic vesicles either recycles back to the releasable pool or fuses with the 
endosome where mature vesicles subsequently bud off [44]. The FM
®
4-64 fluorescent 
probe is commonly used to label synaptic vesicles for live-cell imaging of synaptic 
function [45]. Upon neuronal stimulation, the synaptic vesicles will release the dye 
through exocytosis. The decrease in dye intensity over a period of time indicates the rate 
of exocytosis. Our results showed that after treatment with oligomeric Aβ and CORT, 
dye exocytosis was slower (Fig. 3). These results indicate that the observed pathological 
changes affect synaptic functions by delaying exocytosis and perhaps the release of 
neurotransmitters.  
 
4.2 Protein degradation and the synapse 
 
 To further elucidate the mechanisms underlying the synaptic protein damages, 
protein degradation mechanisms were investigated. The major cellular protein 
degradation pathways are the ubiquitin-proteasome system and the autophagy-lysosomal 
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pathway. Ubiquitin appears to be a common denominator in targeting unwanted proteins 
for degradation by both pathways. Also, ubiquitinated proteins are consistently present in 
protein aggregates found in many neurodegenerative diseases [46].  
  
Ubiquitination involves a cascade of enzymes including ubiquitin-activating 
enzymes (E1), conjugating enzymes (E2), and ligases (E3) [47]. E1 binds to ubiquitin and 
ATP to form a complex. Ubiquitin is then passed on to E2. Ubiquitin-charged E2 then 
forms a complex with an E3 ligase and a protein substrate. Ubiquitin is then transferred 
onto the protein substrate. Studies have shown that if the protein substrate is linked to the 
lysine 48 residue of ubiquitin, the substrate is signaled for degradation by the proteasome. 
On the other hand, if the polyubiquitin chain is formed by the linkage of the substrate to 
the lysine 63 residue, the substrate is preferentially degraded by the lysosome[48].  
 
Our results showed that there was an increase in ubiquitin-48 and -63 
immunoreactivities in both Aβ and CORT treated groups (Fig. 4). At the synaptic level, 
our findings support previous studies that investigate the crucial involvement of protein 
degradation mechanisms in maintaining proper synaptic functions. Ubiquitin has been 
known to function locally at the synapse [49] and several ubiquitin related enzymes have 
been found to regulate synaptic functions [50]. Furthermore, several synaptic proteins are 
substrates for ubiquitin, including synaptophysin [51].  
 
Our results also showed that ubiquitin-63 significantly co-localized with 
synaptophysin for both treatment groups, while ubiquitin-48 did not (Fig. 4). Pathological 
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accumulation of autophagic vacuoles has been observed in AD brains [52, 53]. Up-
regulation of the autophagy-lysosomal degradation pathway has been shown to increase 
production and accumulation of intracellular Aβ [54]. Our observations suggest that up-
regulation of this degradation pathway is also associated with CORT induced toxicity, 
providing another evidence for the similarities between depression and AD. 
 
Higher levels of co-localization between ubiquitin-63 and synaptophysin after 
treatment with Aβ and CORT would suggest increased activation of ubiquitin-mediated 
protein degradation that preferentially signals for autophagy-lysosomal degradation 
pathway. Treatment with CORT or Aβ did not induce changes in any of the three 
proteolytic activities of the proteasome (Fig. 5), supporting the notion that following 
treatment, the autophagy-lysosomal pathway may play a more prominent role compared 
to the ubiquitin-proteasome pathway. 
 
To further elucidate the activation of the autophagic pathway, we performed 
immunocytochemical analysis for LC3-II, which is a marker for autophagosomes [55] 
(Supplementary Fig. 5). LC3-II is a protein located on the inner and outer membrane of 
autophagosomes. Ubiquitinated proteins at lysine 63 recruit the LC3-interacting protein 
p62. p62 is then recognized by LC3-II. Protein substrate tagged with ubiquitin-63, p62 
and LC3-II forms a complex which is then engulfed by the autophagosome, and 
subsequently degraded by the lysosomes [56]. In accordance with the increased 
immunoreactivity of ubiquitin-63 in Aβ and CORT treated cells, there was also an 
increase in the number of LC3-II puncta following treatment. Therefore, in our study, we 
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demonstrated that increased activation of the ubiquitin-mediated autophagy-lysosomal 
degradation pathway induced by either CORT or Aβ, which may contribute to the 
pathological changes in pre-synaptic proteins and its functions. 
 
The role of protein degradation at the synapse is to maintain its plasticity; 
however, the imbalance in the degradation process may disturb synaptic functions [57]. 
Protein degradation mechanisms are important in maintaining proper synaptic function 
and its dysfunction could have detrimental results in the synapse. Although the 
involvement of ubiquitinated proteins and autophagy has been widely investigated in AD 
pathology, it is not well studied in depression. This study suggests the possible 
importance of its role in the pathology of depression. Since modulation of the autophagy-
lysosomal protein degradation pathway has been shown to lead to numerous 
neurodegenerative diseases, its involvement in depression provides new insight as to why 
depressed patients may develop neurodegenerative diseases such as AD later on in life. 
 
4.3 Antidepressants are able to alleviate pre-synaptic protein damages 
 
According to our findings, synaptic degeneration may be an upstream 
pathological process in depression in AD. Our results demonstrated that the selected 
antidepressants were able to alleviate the observed synaptic damage. The use of various 
antidepressants have long been used in treating depressive disorders [58]. Several classes 
of antidepressants are available, including tricyclic antidepressants (TCA) and the 
selective serotonin reuptake inhibitors (SSRI) [59, 60]. Several studies have shown that 
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SSRIs are able to improve cognition and depressive symptoms in both animal models and 
AD patients [5, 61, 62]. However, a recent clinical trial of the SSRI Sertraline, and the 
noradrenergic and specific serotonergic antidepressant Mirtazapine failed to show any 
effects over placebo in the treatment of depression in AD patients [63].  
 
We selected one of the “classical” TCA Imipramine and the newer SSRI 
Escitalopram for our study to investigate whether these antidepressants would be able to 
protect neurons from the toxic effects induced by Aβ and CORT. Our study showed that 
both antidepressants could attenuate the loss or aggregation of synaptic proteins (Fig. 6). 
Interestingly, Imipramine and Escitalopram are two different classes of antidepressants, 
with Imipramine being non-specific, while Escitalopram being highly specific to the 
serotonergic system. This suggests that the modulation of serotonin uptake transporters 
may not be the only underlying mechanism involved. It would be interesting to further 
investigate other possible underlying pathways of how antidepressant affects synaptic 
proteins. 
 
It is important to note that the pathogenesis of depression and AD does not only 
involve synaptic degeneration. Although the present study has shown that synaptic 
degeneration and ubiquitin-mediated protein degradation mechanisms are involved in 
depression and AD, other factors including neuroinflammation, oxidative stress, and 
neurotransmitter dysregulation cannot be excluded. Since we have utilized an in vitro 
disease model for this study, we were only able to investigate the effects of CORT as a 
model for depression and oligomeric Aβ as a model for AD. Other factors involved in 
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each disorder were not investigated including monoamine deficiency for depression and 
NFT for AD. 
 
Depression appears to share similar neurodegenerative processes as AD. We have 
provided significant evidence to show that synaptic degeneration is a common 
pathological feature of both depression and AD.  The observed synaptic protein loss and 
aggregation appeared to be associated with the ubiquitin-mediated autophagy-lysosomal 
pathway. Since the involvement of this pathway is not well studied in depression, our 
study provides new insight into the pathology of depression and further supports the idea 
that similar molecular neuropathology exists between depression and AD. Moreover, our 
observation that antidepressants were able to alleviate the synaptic pathologies, 
implicates that the prevention of synaptic degeneration may be pivotal in the early 
therapeutic intervention of these two disorders and further investigations are highly 
warranted. 
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Figure legends 
 
Figure 1. Low-dose oligomeric Aβ induced aggregation of pre-synaptic proteins at 12 hr 
and loss of pre-synaptic proteins at 24 hr. A & D) Treatment with 0.5 μM Aβ for 24 hr 
caused a reduction in the number of immunoreactive puncta of synaptophysin and 
synaptotagmin while aggregations of these proteins were observed after 12 hr treatment. 
Live-cell imaging of primary hippocampal neurons transduced with CellLight
® 
Synaptophysin-GFP also showed reduction in immunoreactive positive puncta. Images 
were taken at 63x objective (scale bar 10 μm) B,C,E,F,G). Quantitative analysis of the 
number of puncta and aggregations was performed by MacBiophotonics Image J. Results 
were expressed as fold of control ± SE from at least 3 independent experiments. 
Statistical analysis was performed by unpaired t-test. * represents p<0.05 compared to the 
corresponding control. H) Western-blot analysis of pre-synaptic proteins showed reduced 
protein levels. I) Quantitative analysis of western blot by MacBiophotonics Image J. 
Results were expressed as fold of control ± SE from at least 3 independent experiments. 
Statistical analysis was performed by one-way ANOVA, followed by the post hoc 
Tukey’s test. * represents p<0.05 compared to the corresponding control.  
 
Figure 2. Low-dose CORT induced aggregation of pre-synaptic proteins. A) Staining for 
synaptotagmin and synaptophysin showed that treatment with 0.5 μM CORT for 24 hr 
induced protein aggregations. Live-cell imaging of primary hippocampal neurons 
transduced with CellLight
® 
Synaptophysin-GFP also showed pre-synaptic protein 
aggregations under the same conditions. Images were taken at 63x objective (scale bar 10 
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μm). B-D) Quantitative analysis of the immunoreactivity was performed by 
MacBiophotonics Image J. The amount of aggregation of synaptophysin and 
synaptotagmin after treatment was found to be significantly increased. Aggregations were 
defined by size of the puncta over number of puncta. Results were expressed as fold of 
control ± SE from at least 3 independent experiments. Statistical analysis was performed 
by unpaired t-test. * represents p<0.05 compared to the corresponding control. E) 
Western-blot analysis showed no change in protein expression levels of synaptic proteins 
after treatment with 0.5 and 5 μM CORT for 24 hr. F) Quantitative analysis of Western-
blot was performed by MacBiophotonics Image J. Results were expressed as fold of 
control ± SE from at least 3 independent experiments. Statistical analysis was performed 
by one-way ANOVA, followed by the post hoc Tukey’s test.  
 
Figure 3. Low-dose oligomeric Aβ and CORT slowed down FM®4-64 dye release, hence 
exocytosis. A) FM
®
4-64 dye was used to investigate endocytosis (dye uptake, increase in 
fluorescent intensity) and exocytosis (dye release, decrease in fluorescent intensity). 
Images shown represent dye uptake and release specifically at the neurites. B) 
MacBiophotonics Image J was used to quantify the fluorescent intensities of FM
®
4-64 
dye. Results showed similar fluorescent intensities during dye uptake, indicating that 
endocytosis was unaffected. However, during exocytosis when the dye was supposed to 
be released (and the subsequent decrease in fluorescent intensity), C) fluorescent intensity 
of the treated neurons remained at an elevated level. This indicates that the fluorescent 
probe was not being properly released; hence exocytosis appeared to be slower in treated 
neurons. Results were expressed as fold of control ± SE from at least 3 independent 
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experiments. Statistical analysis was performed by unpaired t-test. * & ** represent 
p<0.05 and p<0.01 compared to the corresponding control. Images were taken at 63x 
objective (3x digital zoom; scale bar 10 μm). 
 
Figure 4. Low-dose oligomeric Aβ and CORT induced ubiquitin-mediated protein 
degradation mechanisms. A) Primary hippocampal neurons were examined for 
synaptophysin and ubiquitin-48 immunoreactivity. Increase in the number of positive 
ubiquitin-48 puncta and co-localization with synaptophysin (indicated by arrows) was 
observed. Lactacystin at 10 μM served as a positive control. B) Quantification of the 
immunoreactivity was performed by MacBiophotonics Image J. There was a significant 
increase in number of puncta after treatment. Results were expressed as fold of control ± 
SE from at least 3 independent experiments. Statistical analysis was performed by one-
way ANOVA, followed by the post hoc Tukey’s test. *, **, & *** represent p<0.05, 
p<0.01, and p<0.001compared to the corresponding control. C) Mander’s coefficient for 
co-localization analysis showed no significant increase in the co-localization level in the 
treated group, except in the lactacystin treated neurons. Statistical analysis was performed 
by one-way ANOVA, followed by the post hoc Tukey’s test. * represents p<0.05 
compared to the corresponding control. D) Primary hippocampal neurons were examined 
for synaptophysin and ubiquitin-63 immunoreactivity. Increase in the number of 
ubiquitin-63 puncta and co-localization with synaptophysin (indicated by arrows) was 
observed. Lactacystin-treated cells served as a positive control. E) Quantification of the 
immunoreactivity was performed by MacBiophotonics Image J.  There was a significant 
increase in number of puncta after treatment. Results were expressed as fold of control ± 
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SE from at least 3 independent experiments. Statistical analysis was performed by one-
way ANOVA, followed by the post hoc Tukey’s test. *, **, & *** represents p<0.05, 
p<0.01, and p<0.001 compared to the corresponding control. F) Mander’s coefficient for 
co-localization analysis showed a significant increase in the co-localization level of 
synaptophysin and ubiquitin-63 in the treated group. Statistical analysis was performed 
by one-way ANOVA, followed by the post hoc Tukey’s test. *, **, & *** represent 
p<0.05, p<0.01, and p<0.001, respectively, compared to the corresponding control. 
Images were taken at 63x objective (3x digital zoom; scale bar 10 μm). 
 
Figure 5. Low-dose oligomeric Aβ and CORT did not mediate changes in proteasome 
activity. Primary hippocampal neurons were treated with 0.5µM Aβ and CORT and 
analysed for proteasome activity using a fluorescence activity assay. No significant 
changes in the chymotrypsin-like, trypsin-like, and caspase-like activities of the 
proteasome were found after treatment with low dose oligomeric Aβ and CORT. Results 
were expressed as fold of control ± SE from 4 independent experiments. Statistical 
analysis was performed by one-way ANOVA followed by the post hoc Tukey’s test.  
 
Figure 6. A) Antidepressants Imipramine and Escitalopram were able to alleviate the 
observed synaptic pathologies after low-dose oligomeric Aβ treatment. Primary 
hippocampal neurons were pre-treated for 1 hr with Imipramine or Escitalopram. 
Immunostaining of synaptophysin and synaptotagmin showed an increase in number of 
puncta. Plus signs indicate antidepressant pre-treatment followed by oligomeric Aβ 
treatment. B&C) Quantification of immunostaining was performed by MacBiophotonics 
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Image J. Results showed that the number of puncta increased significantly after Aβ 
treatment. Results were expressed as fold of control ± SE from at least 3 independent 
experiments. Statistical analysis was performed by one-way ANOVA followed by the 
post hoc Tukey’s test. * represents p<0.05 compared to 0.5 μM Aβ. D) Antidepressants 
Imipramine and Escitalopram were able to alleviate the observed synaptic pathologies 
after low-dose CORT treatment. Primary hippocampal neurons were pre-treated for 1 hr 
with Imipramine or Escitalopram. Immunofluorescent analysis of synaptophysin and 
synaptotagmin showed a reduction in protein aggregation. Plus signs indicate 
antidepressant pre-treatment followed by CORT treatment. E &F) Quantification of 
immunostaining was performed by MacBiophotonics Image J. Results showed that the 
number of aggregations was significantly reduced after CORT treatment. Results were 
expressed as fold of control ± SE from at least 3 independent experiments. Statistical 
analysis was performed by one-way ANOVA followed by the post hoc Tukey’s test. * 
represents p<0.05 compared to 0.5 μM CORT. Images were taken at 63x objective (scale 
bar 10 μm). 
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Materials and methods 
 
Preparation of oligomeric Aβ1-42 
 
 Preparation of oligomeric Aβ1-42 was according to Lai et al., 2009 [1]. Synthetic 
human Aβ1-42 was purchased from the W.M. Keck Foundation Biotechnology Research 
Laboratory, Yale University (New Haven, USA). The peptide powder was dissolved in 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Sigma-Aldrich) to achieve the concentration 
of 2 mM of Aβ1-42 peptides. HFIP was then evaporated from the peptide solution. The 
remaining peptides were resuspended in anhydrous DMSO (Sigma-Aldrich), incubated in 
a bath sonicator for 30 min at room temperature, aliquoted and snap frozen in liquid 
nitrogen. The aliquoted peptide was then dissolved in culture medium to the desired 
concentration for treatment. Tris-Tricine gel electrophoresis was performed to examine 
the species of Aβ1-42 peptides within the preparation. The membrane was then incubated 
with mouse monoclonal anti-human Aβ (6E10) antibody (Signet, Hayward, CA, USA), 
followed by horseradish peroxidase-conjugated secondary antibody. Bands were 
visualized on Biomax X-ray film using ECL spray (Upstate, Syracuse, NY, USA). 
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Preparation of primary hippocampal cultures 
 
 Primary hippocampal neurons were prepared from embryonic day 18 Sprague-
Dawley rats according to Lai et al., [1] (Laboratory Animal Unit, The University of Hong 
Kong, accredited by Association for Assessment and Accreditation of Laboratory Animal 
Care International. Approval for conducting experiments was obtained from the 
Committee on the use of Live Animals in Teaching and Research, The University of 
Hong Kong). Isolated hippocampi were dissociated in 1x PBS solution supplemented 
with 18 mM glucose and cultured on poly-L-lysine (25 µg/ml) coated 6-well plates (Iwaki, 
Japan), 12-well plates (Iwaki) with cover slips (Thermo Scientific), or MatTek culture 
dishes (MatTek, Ashland, MA, USA). Neurons were seeded at 6.5 x 10
5
, 7.5 x 10
4 
and 
1.5 x 10
5 
cells per well, respectively. Neurons were cultured in Neurobasal
®
 medium 
(GIBCO-BRL, Rockville, MO, USA) supplemented with B-27, 2 mM L-glutamine, 10 
μg/ml penicillin/streptomycin and 25 μM β-mercaptoethanol. Deoxyfluoridine was added 
to inhibit the growth of non-neuronal cells 1 day after seeding. Neurons were kept in a 
humidified incubator at 37°C and 5% CO2 for 14 days prior to treatment. 
 
Cell Culture of SH-SY5Y 
 
Human neuroblastoma cell line SH-SY5Y cells were purchased from American 
Type Culture Collection (ATCC). Cells were cultured in supplemented MEM (2 mM L-
glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin) with 10% heat-inactivated 
FBS and kept in a humidified incubator at 37˚C and 5% CO2. Cells were seeded at 2 x 
10
5
 per well in 6-well plates for 2 days then treated with 1 or 5 µM of Aß and CORT for 
24 and 48 hr.  
 
Transfection 
 
 Neurons were cultured on MatTek glass-bottom dishes for transfection and live-
cell imaging (Carl Zeiss, LSM510-Meta system). Transfection was done at DIV 7 for 4 hr 
with Lipofectamine 2000 (Invitrogen), treated on day 13 and analyzed 24 hr after 
treatment. Lipofectamine allows for high transfection efficiency and low neuronal 
toxicity [2]. PSD95-YFP was a gift from Prof. Rachel Wong (University of Washington, 
USA). Neurons were imaged using the LSM510 confocal microscope and images were 
quantified using MacBiophotonics Image J.  
 
Cytotoxicity assay 
 
 Cytotoxicity was determined by the Cytotoxicity Detection kit (Roche, Mannheim, 
Germany) as described previously [3]. The assay measures LDH activity released from 
damaged cells. Briefly, culture medium was centrifuged and cell-free supernatant was 
collected and incubated in a 96-well plate with equal volumes of assay reagents (1 μl of 
reagent 1 to 44 μl of reagent 2) in the dark for 30 min. Absorbance was measured at 492 
nm using the Multiskan Spectrum spectrophotometer. Results were expressed as fold of 
control. 
 
Cell viability assay 
 
Cell viability was measured by the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide]  (MTT) assay (Roche) as described previously [4]. In short, cells 
were incubated with MTT assay reagent 1 for 4 hr at 37˚C and 5% CO2, followed by an 
overnight incubation period with reagent 2 at 37˚C and 5% CO2. Absorbance was 
measured at wavelength 550 nm with reference wavelength at 690 nm by a microplate 
reader. Results were expressed as percentage of viable cells. 
 
Caspase-3-like activity assay 
 
After treatment with CORT and Aβ, cells were lysed using the caspase lysis 
buffer (1.192 g HEPES, 77.1 mg DTT, 2.95 mg EDTA, 0.002% Triton X-100, 100 ml 
milliQ H2O) for caspase-3-like activity assay as described previously [5]. Total protein 
lysate was extracted to perform a protein assay to determine protein concentration, and 50 
μg of protein was mixed with caspase-3 substrate (Ac-DEVD-pNA, 4 mM; Calbiochem), 
DTT (1 M) and 2X reaction buffer (50 μl), to a total volume of 100 μl. The mixture was 
duplicated for each sample and added into each well of a 96-well plate. The plate was 
then incubated at 37ºC for 2 hr and absorbance was measured at 405 nm using the 
Multiskan Spectrum spectrophotometer. Values of specific activity (pmol/min/μg) were 
calculated from the absorbance readings. Results were expressed as fold of control. 
 
 
Antibodies 
 
For western blot analysis, primary antibodies Bad (1:1000), Bax (1:1000), and 
phospho-Bcl-2 (1:1000) were incubated overnight at 4˚C (Cell Signaling). Bcl-2 (1:1000) 
(BD Biosciences) and PSD95 (1:2000) (Cell Signaling) were incubated for 4 hr at room 
temperature. β-actin (1:10000) was incubated for 1 hr at room temperature (Abcam).  
For immunocytochemical analysis, PSD95 (1:400) (Synaptic System, Göttingen, 
Germany) was incubated for 1 hr at room temperature. 
 
Analysis of fluorescent images  
 
Quantitative measurements for intensity, puncta size and number of puncta were 
obtained by MacBiophotonics Image J. Protein aggregations were defined by size of 
puncta divided by number of puncta. Puncta quantification and co-localization analysis 
were performed using the Particle Analysis and Co-localization Analysis plug-in for 
MacBiophotonics Image J, respectively. 
 
 
 
 
 
 
 
Results 
 
Determination of CORT toxicity 
 
LDH, MTT, and caspase-3-like activity assays were used to determine toxic 
concentrations of CORT to neurons. Ten micromolar of CORT for 24 hr induced 
neuronal cell death compared to control as seen by increased LDH release and caspase-3-
like activity (Supplementary Fig. 1 A & B). MTT assay showed a significant decrease in 
percentage of viable cells after 24 hr treatment of 10 μM CORT (Supplementary Fig. 1 
C). Treatment with 0.5 μM CORT was selected for subsequent experiments as observable 
changes to the pre-synaptic protein synaptophysin was observed without affecting cell 
viability (Supplementary Fig. 1 D). 
 
Co-treatment with oligomeric Aβ and CORT did not induce changes in apoptotic 
marker expression 
 
Since glucocorticoids have been found to increase neuronal vulnerability to 
treatments of various toxins [6], SH-SY5Y human neuroblastoma cells were co-treated 
with 1 or 5 μM of Aβ and CORT for 24 and 48 hr to examine whether CORT treatment 
would affect cell vulnerability in Aβ treated cells. Treatment of CORT did not induce 
changes to Bad or Bax expression or the ratio of phospho-Bcl-2 to Bcl-2 in cells also 
treated with Aβ (Supplementary Fig. 2), indicating that the presence of CORT does not 
affect neuronal survival in these cells.   
Oligomeric Aβ and CORT caused post-synaptic damage 
 
To investigate post-synaptic damage after Aβ and CORT treatment, primary 
hippocampal neurons were stained for PSD95 or transfected with PSD95-YFP. Both 
oligomeric Aβ and CORT treatment at 0.5 μM for 24 hr did not cause any statistically 
significant changes in number of puncta, number of aggregations or protein expression 
level of PSD95 (Supplementary Fig. 3 & 4). 
 
Figure legends 
 
Supplementary 1. Determination of CORT toxicity on primary culture of hippocampal 
neurons. A) Treatment of hippocampal neurons with CORT for 24 hr induced release of 
LDH significantly at 10 μM and above. Results were expressed as fold of control ± SE 
from at least 3 independent experiments. Statistical analysis was performed by one-way 
ANOVA, followed by the post hoc Tukey’s test. * represents p<0.05 compared to the 
control.  B) Treatment of primary hippocampal neurons for 24 hr with 10 μM CORT was 
able to significantly increase caspase-3-like activity, indicative of activation of 
downstream pathways involved in apoptosis. Results were expressed as fold of control ± 
SE from at least 3 independent experiments. Statistical analysis was performed by one-
way ANOVA, followed by the post hoc Tukey’s test. * represents p<0.05 compared to 
control. C) MTT assay results showed treatment of primary hippocampal neurons for 24 
hr with CORT did not significantly affect the cell viability up to 10 μM. Treatment with 
10% Triton X-100 served as a negative control. Results were expressed as percentage of 
viable cells ± SE from at least 3 independent experiments. Statistical analysis was 
performed by one-way ANOVA, followed by the post hoc Tukey’s test. * represents 
p<0.01 compared to control. D) Immunocytochemical analysis of synaptophysin showed 
that 0.5 and 1 μM CORT treatment caused observable protein aggregation (shown by 
arrows) using epifluorescent microscope (40x magnification), therefore 0.5 μM CORT 
was selected for subsequent experiments. 
 
Supplementary 2. Low-dose CORT and oligomeric Aβ did not induce changes in apoptotic 
marker expression. A) Western blot analysis of SH-SY5Y cells treated with 1 and 5μM of 
CORT and Aβ for 24 and 48 hr did not show changes in the protein expression levels of Bad 
and Bax or ratio of phospho-Bcl-2 to Bcl-2. B) Quantitative analysis of western blot was 
performed by MacBiophotonics Image J. Results were expressed as fold of control ± SE from 
at least 3 independent experiments. Statistical analysis was performed by one-way ANOVA, 
followed by the post hoc Tukey’s test.  
 
Supplementary 3. Low-dose oligomeric Aβ treatment did not cause significant changes 
to the post-synaptic protein PSD95. A) Primary hippocampal neurons were transfected 
with PSD95-YFP on day 7 and imaged on day 14 or stained for PSD95 after treatment. 
Images were taken at using LSM510 confocal microscope at 63x objective (scale bar 10 
μm). B-E) MacBiophotonics Image J was used to quantify the immunoreactivity by 
counting the number of positive puncta. Results were expressed as fold of control ± SE 
from at least 3 independent experiments. Statistical analysis was performed by unpaired 
t-test. F) Western blot analysis showed significantly reduced PSD95 protein levels after 
treatment with 5 µM Aβ. G) Quantitative analysis of western blot was performed by 
MacBiophotonics Image J. Results were expressed as fold of control ± SE from at least 3 
independent experiments. Statistical analysis was performed by one-way ANOVA, 
followed by the post hoc Tukey’s test. * represents p<0.05 compared to corresponding 
control.  
 
Supplementary 4. Low-dose CORT treatment did not cause significant changes to the 
expression of post-synaptic protein PSD95. A) Primary hippocampal neurons were 
transfected with PSD95-YFP on day 7 and imaged on day 14 or stained for PSD95 after 
treatment. Images were taken with LSM510 confocal microscope at 63x objective (scale 
bar 10 μm). B-E) MacBiophotonics Image J was used to quantify the immunoreactivity 
by counting the number of positive puncta. Results were expressed as fold of control ± 
SE from at least 3 independent experiments. Statistical analysis was performed by 
unpaired t-test. F) Western blot analysis showed no change in PSD95 protein level 
expression. G) Quantitative analysis of western blot was performed by MacBiophotonics 
Image J. Results were expressed as fold of control ± SE from at least 3 independent 
experiments. Statistical analysis was performed by one-way ANOVA, followed by the 
post hoc Tukey’s test.  
 
Supplementary 5. Oligomeric Aβ and CORT increased expression of autophagic marker, 
LC3-II. A) Primary hippocampal neurons were stained for immunoreactivity of LC3-II. 
Low-dose oligomeric Aβ and CORT (0.5 µM) did not significantly increase the number 
of LC3-II puncta compared to respective controls. However, treatment with 10 µM 
oligomeric Aβ and CORT for 24 hr significantly increased the number of LC3-II puncta. 
Lactacystin served as a positive control. Images were taken with LSM510 confocal 
microscope at 63x objective (3x digital zoom; scale bar 10 μm). B) MacBiophotonics 
Image J quantitative analysis showed a significant increase in the number of LC3-II 
puncta with 10 µM of Aβ and CORT but not with 0.5 µM. Results were expressed as fold 
of control ± SE from at least 3 independent experiments. Statistical analysis was 
performed by one-way ANOVA, followed by the post hoc Tukey’s test. *, **, & *** 
represents p<0.05, 0.01, and 0.001, respectively, compared to the corresponding control. 
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